Quote:

---

Obviously one cannot really read into anything Nader says, because the man doesn't really choose his words carefully most of the time. That being said, in the press release, he said "distribution of leronlimab to patients throughout the U.S." THROUGHOUT THE US.

Does this automatically exclude the rest of the world right now, meaning that those other countries have passed on leronlimab at the moment? Overall I doubt it, but again, the man needs to choose his words more carefully sometimes.

---

Well, as a point in fact, CytoDyn has not announced the existence of a signed agreement with an international distribution partner, so they cannot claim to be "well positioned" to distribute anywhere else.

I imagine that even if the FDA demands a Phase 3 for M/M, and even if the UK or Mexico approve M/M, CytoDyn will wait 4-6 weeks for the top-line results of the S/C before selling inventory outside of the US.

I imagine an international distribution agreement has already been negotiated and is just awaiting signatures. Had such an agreement already been executed, CytoDyn would have had to disclose it within 4 business days per the SEC.